Loading organizations...
§ Private Profile · Dublin, Ireland
ProVerum Medical is a technology company.
ProVerum Ltd. is a privately held venture-backed startup focused on developing novel minimally invasive technologies to treat BPH. Their ProVee stent alleviates Lower Urinary Tract Symptoms by opening the prostatic urethra.
ProVerum Medical has raised $114.0M across 2 funding rounds.
ProVerum Medical has raised $114.0M in total across 2 funding rounds.
ProVerum Medical has raised $114.0M across 2 funding rounds. Most recently, it raised $80.0M Series B in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2025 | $80M Series B | Hugo Harrod | F Prime Capital, Lightstone Ventures, ALI Behbahani, Tiffany LE, Atlantic Bridge, Enterprise Ireland, Ireland Strategic Investment Fund, Dina Chaya | Announced |
| Jan 1, 2022 | $34M Series A | — | F Prime Capital, Lightstone Ventures, ALI Behbahani, Tiffany LE | Announced |
ProVerum Medical has raised $114.0M in total across 2 funding rounds.
ProVerum Medical's investors include Hugo Harrod, F-Prime Capital Partners, Lightstone Ventures, Ali Behbahani, Tiffany Le, Atlantic Bridge, Enterprise Ireland, Ireland Strategic Investment Fund, Dina Chaya.
ProVerum Medical is a Dublin-based medtech company developing the ProVee System, a minimally invasive nitinol stent for treating benign prostatic hyperplasia (BPH), which causes lower urinary tract symptoms (LUTS) in aging men.[1][2][3][5] The device gently reshapes the enlarged prostate without cutting, burning, or piercing tissue, enabling office-based procedures with rapid recovery, reversibility, and universal sizing for all indicated anatomies.[2][3][5] It serves urologists and BPH patients, addressing a validated problem affecting over 25% of men over 50 by offering a safer, first-line interventional therapy (FIT) alternative to surgery.[1][4][5] Founded in 2016, the company has raised $38.58M total, including a €68.6M Series B in September 2025, completed its ProVIDE pivotal trial enrollment in April 2024, and secured FDA approval on December 9, 2025, positioning it for U.S. commercialization.[1][2][3]
ProVerum Medical was founded in 2016 by Dr. Ríona Ní Ghriallais and Dr. Conor Harkin, an alumnus of the University of Galway's BioInnovate program, spinning out from Trinity College Dublin.[2] The idea emerged from their focus on innovative, minimally invasive solutions for BPH, a common condition causing urinary difficulties due to prostate enlargement.[1][2][4] Early support from EIT Health in 2016 provided funding and networking in Ireland, enabling the spin-out and initial development of the ProVee System.[2] Pivotal moments include completing enrollment in the ProVIDE pivotal clinical trial in April 2024 using a new flexible, steerable delivery system, securing €68.6M Series B funding led by MVM Partners in September 2025, and achieving FDA approval for the ProVee System on December 9, 2025.[1][2][3]
ProVerum rides the trend toward minimally invasive, office-based urology treatments, capitalizing on aging populations driving BPH prevalence (over 25% of men >50).[1][4] Timing aligns with post-pandemic demand for outpatient procedures reducing hospital burdens, faster recoveries, and lower costs versus traditional surgeries like TURP.[2][3][5] Market forces favoring medtech innovation—such as FDA approvals for next-gen stents and investor interest (e.g., MVM, OrbiMed, EIT Health)—support scalability.[2][3] ProVerum influences the ecosystem by pioneering prostatic urethral stents as FITs, potentially shifting standards with atraumatic, reversible options and robust clinical data, encouraging similar device advancements in men's health.[1][3][5]
With FDA approval secured, ProVerum is poised for U.S. market launch and global expansion of the ProVee System, leveraging Series B funds for commercialization and ongoing follow-ups from ProVIDE and cross-over studies.[1][2][3] Trends like rising BPH incidence, AI-enhanced diagnostics, and value-based care will amplify demand for its efficient, patient-centric model. Its influence may grow by redefining BPH care as accessible office therapy, drawing more investment into urological medtech and solidifying ProVerum as a leader in prostate health innovation—transforming lives for millions affected by LUTS.[3][5]